Table 3.

Adjusted means of IGF-I and IGFBP-3 by quartiles of percent density stratified by history of hormone therapy use

Never used hormone therapy (n = 45)
Former users of hormone therapy (n = 43)
Used hormone therapy <5 y ago (n = 20)
Used hormone therapy ≥5 y ago (n = 19)
Adjusted hormone levels by quartiles of percent density* (95% CI)Adjusted hormone levels by quartiles of percent density* (95% CI)Adjusted hormone levels by quartiles of percent density (95% CI)Adjusted hormone levels by quartiles of percent density (95% CI)
IGF-I (ng/mL)94.1 (73.6-114.6)115.5 (97.4-133.7)127.0 (91.2-162.9)115.2 (87.8-142.6)
111.1 (93.9-128.2)116.3 (94.1-138.5)118.6 (79.0-158.1)117.4 (74.5-160.3)
117.4 (98.5-136.4)110.9 (90.1-131.8)105.0 (69.5-140.5)115.2 (72.8-157.7)
105.2 (85.4-125.1)101.4 (82.1-120.7)97.5 (64.1-131.0)100.8 (58.5-143.1)
    P for trend0.400.190.180.50
IGFBP-3 (μg/mL)3.8 (3.1-4.4)3.7 (3.1-4.3)3.7 (2.6-4.8)3.7 (2.9-4.5)
4.4 (3.9-5.0)4.1 (3.3-4.8)4.7 (3.5-5.9)3.4 (2.1-4.7)
3.4 (2.8-4.0)3.9 (3.2-4.6)4.4 (3.3-5.5)3.7 (2.4-5.0)
4.1 (3.5-4.8)4.4 (3.8-5.1)4.3 (3.3-5.3)4.0 (2.7-5.3)
    P for trend0.900.290.530.91
IGF-I/IGFBP-324.8 (20.5-30.1)30.8 (26.0-36.4)32.8 (25.3-42.5)31.2 (25.6-3.81)
24.1 (20.5-28.3)28.6 (23.2-35.2)25.0 (18.8-33.2)34.7 (25.4-47.3)
36.3 (30.4-43.3)8.9 (23.8-35.1)3.8 (18.4-30.8)1.8 (23.4-43.2)
25.1 (20.9-30.2)23.1 (19.3-27.7)22.7 (17.8-28.8)25.3 (18.6-34.4)
    P for trend0.250.040.050.44
  • * Quartiles of percent density: first quartile: 0.2% to 2.75% (n = 9 never users and 13 former users); second quartile: 2.8% to 4.9% (n = 14 never users and 8 former users); third quartile: 5.1% to 7.5% (n = 11 never users and 11 former users); and fourth quartile: 7.5% to 26.1% (n = 11 never users and 11 former users). Adjusted for age, ethnicity, years since menopause, and percent body fat.

  • Quartiles of percent density: first quartile: 0.2% to 2.75% (n = 4 users <5 years and 8 users ≥5 years); second quartile: 2.8% to 4.9% (n = 4 users <5 years and 4 users ≥5 years); third quartile: 5.1% to 7.5% (n = 6 users <5 years and 4 users ≥5 years); and fourth quartile: 7.5% to 26.1% (n = 6 users <5 years and 3 users ≥5 years). Adjusted for age, ethnicity, years since menopause, and percent body fat.

  • P < 0.05, compared with first quartile.